Spirulina Oral Supplement for Enhancing Host Resilience to Virus Infection

Description

This randomized, double blind, placebo controlled study aims to establish the impact of the oral supplement, Immulina TM, on enhancing host resilience to the effects of viral influenza infection in humans.

Conditions

Healthy Volunteers

Talk to us

Study Overview

On this page

Study Details

Study overview

This randomized, double blind, placebo controlled study aims to establish the impact of the oral supplement, Immulina TM, on enhancing host resilience to the effects of viral influenza infection in humans.

Impact of Oral Immulina TM on Natural Killer Cell Activities and Other Biomarkers Associated with Increasing Host Immune Resilience to Upper Respiratory Viruses in Normal Human Volunteers

Spirulina Oral Supplement for Enhancing Host Resilience to Virus Infection

Condition
Healthy Volunteers
Intervention / Treatment

-

Contacts and Locations

Jackson

University of Mississippi Medical Center, Jackson, Mississippi, United States, 39216

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Ages 18-59 (study group 1) or ages 65 and above (study group 2)
  • * Any chronic illness must be determined (by PI team) to be stable as evidenced by no changes in medical regimens within 30 days of enrollment.
  • * Ability to comprehend the specific activities required to participate in the trial for which the participant is to be enrolled.
  • * Any acute illness or significant injury within 30 days of enrollment.
  • * Specific disease entities, which, in the opinion of the PI, could reasonably be assumed to have dysfunctional immune function as a component of their illness. These include HIV, AIDS, uncontrolled asthma, uncontrolled eczema, uncontrolled allergic rhinitis, uncontrolled urticaria, Rheumatoid arthritis, lupus, inflammatory bowel disease, multiple sclerosis, Type-1 diabetes mellitus, Guillain-Barr syndrome, Grave's disease, Hashimoto's thyroiditis, myasthenia gravis or vasculitis.
  • * Active autoimmune diseases regardless of clinical stability. A history of autoimmune disease that is not considered active (i.e. no medical therapy for at least 1 year prior to enrollment) will not be excluded.
  • * History of unstable chronic illness within 30 days of enrollment.
  • * Unable/unwilling to commit to multiple research clinic visits which will be described in detail.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

University of Mississippi Medical Center,

Gailen D Marshall, Jr., MD, PhD, PRINCIPAL_INVESTIGATOR, University of Mississippi Medical Center

Study Record Dates

2026-06-30